Fludarabine

CAR-T

Zhimin ZhaiSmall moleculeEarly Phase 1Active

C

39/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 24/ 100
Competitive Position: 89/ 100

Competitive context

4 Active assets in the CAR-T cohort.

Asset / Sponsor	Phase	Rating
c752 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	Phase 1	CC
Promethazine Zhimin Zhai	Early Phase 1	C
Chimeric Antigen Receptor Modified T Cells Infusion Zhimin Zhai	Early Phase 1	C
Cyclophosphamide Zhimin Zhai	Early Phase 1	C

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant

BBB

Indicative ·

76 / 100

Fanconi anemiaDormant

BBB

Indicative ·

76 / 100

Recurrent Adult Diffuse Large Cell LymphomaDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.